ABSTRACT Positively charged peptides [(Arg) 7 Cys] were successfully linked to tissue-specific plasminogen activator (tPA) using cross-linking agent N-succinimidyl 3-(2-pyridyldithio) propionate. Specific amidolytic activity of this tPA/(Arg) 7 Cys (termed modified tPA, mtPA) was 3900 IU/μg as compared to 5800 IU/μg of the parent tPA. Both activation of plasminogen with mtPA (K m = 2.7 mM -1 ) and tPA (K m = 1.1 mM -1 ) in a purified system followed Michaelis-Menten kinetics. In addition, (Arg) 7 Cys modification did not result in significant changes in the fibrin-binding ability of tPA, and mtPA still retained a response to fibrinogen similar to that of the parent tPA. Compared with tPA, mtPA showed much stronger heparin affinity, and the heparin/mtPA complex was stable in human plasma. The activity of mtPA in such a complex was inhibited by heparin, and, unlike tPA, the heparin/mtPA complex did not cause statistically meaningful depletion of plasminogen, fibrinogen, and α 2 -antiplasmin in plasma. Using the chromogenic and the in vitro clot lysis assay, it was demonstrated that the heparin-induced inhibition of the mtPA activity was easily reversed following the addition of an adequate amount of protamine. To enhance the clottargeting efficiency of the heparin/mtPA complex further, anti-fibrin immunoglobulin (IgG) was conjugated to heparin via an end-point attachment of heparin to the sugar moieties in the Fc region of the IgG. Results show that the activity of mtPA could also be blocked by the heparin/anti-fibrin IgG conjugate. These findings suggest the applicability of
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INTRODUCTION
Several characteristics, such as being specific, efficient, and optimally active at physiologic temperatures, make enzymes especially suitable as therapeutic drugs. Conversely, enzymes also have a number of undesirable characteristics: they are relatively bulky and exhibit limited stability in circulation. The primary reasons for the lack of clinical application of enzymes, however, lie in their potential immunogenicity, as well as their indiscriminate actions toward both target and normal substrates (1) (2) (3) . To reduce the immunogenicity and increase the life span of enzymes, much effort has been directed towards chemically modifying the enzyme with dextran, polyethylene glycol (2,3), etc, or encapsulating the enzyme in human red blood cells (4) . It has been proven that such chemical modifications and red cell encapsulation are effective in improving the pharmacokinetic profile and decreasing the immunogenicity of enzymes (4). The inability of an enzyme to distinguish between the target and normal substrates, however, will yield unwanted toxic effects and thus still stands as the major hurdle to its use as a clinical drug.
Thrombolytic agents, namely plasminogen activators, include streptokinase, urokinase, and tissue-specific plasminogen activator (tPA). They convert the proenzyme plasminogen to the active enzyme plasmin, which in turn digests the fibrin clot. Plasmin, however, is a relatively nonspecific protease that modifies platelet function (5) and also degrades circulating fibrinogen and clotting factors V and VIII (6) . Hence, thrombolytic therapy, which introduces systemic generation of excess plasmin, also carries the risk of hemorrhage as a major side effect. Clinically, thrombolytic agents are widely used in the treatment of established thrombus in myocardial infarction and pulmonary embolism (7) (8) (9) (10) (11) . With the advent of thrombolytic therapy, early mortality from acute myocardial infarction has been reduced by approximately one third (from 10-15% to 5-10%) (12) . Despite the major advances made in the last decade, the most effective regimen so far is still the "front-loaded" recombinant tPA regimen. However, it still possesses a high patient mortality rate of 6.3% for 30-day mortality and is associated with fatal cerebral hemorrhage in 1.5% of patients (13) . At present, approximately 1.5 million Americans suffer an acute myocardial infarction annually. Because the beneficial effects of thrombolytic therapy have been well established, the need for a more selective plasminogen activator still remains.
Previously, we reported a novel heparin/protaminebased enzyme delivery system (14) that could be employed to deliver a PA drug without its associated bleeding risk. As shown in Figure 1 , this system is composed of a large complex made of 2 components: (1) a targeting component consisting of an antibody chemically linked with an anionic heparin molecule and (2) a drug component consisting of PA derivatized with cationic species. Because the cations used are relatively small (eg, a positively charged peptide), the modified PA should be able to retain a significant level of its proteolytic activity. The modified PA, however, would be deprived of such activity once it binds to the antibody/heparin counterpart, presumably attributable to blocking of the PA's active sites by these appended macromolecules. The 2 components are linked via a tight but reversible electrostatic interaction. Therefore, similar to a "prodrug" type approach, the modified PA would be without proteolytic activity during administration, thereby alleviating the bleeding risk produced by systemic activation of circulating plasminogen. After targeting the thrombus by the attached anti-fibrin antibody, the active modified PA could then be released locally at the sites of the clot by using the triggering agent protamine, which is the clinical heparin antagonist that binds heparin with even stronger affinity than the cationic species. Because both heparin and protamine are FDA-approved drugs and because heparin is used concomitantly with tPA in clinical practice to reduce the risk of recurrent thrombosis, this approach is especially suitable for tPA delivery because it does not introduce any new agents that are not currently used in thrombolytic therapy. Steps have also been taken to ensure the successful application of the system in vivo by taking into consideration the various blood proteins that can compete for heparin binding. The heparin-binding strength of the cationic specie is chosen so that the hep-IgG/PA complex can remain intact while in circulation, and the successful release of mtPA can be achieved at the clot site with protamine.
In this work, positively charged peptides [(Arg) 7 Cys] were linked to tPA using the heterobifunctional cross-linking reagent N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) (15) . Results showed that the modified tPA (mtPA) still maintained a significant level of its catalytic activity. As anticipated, this activity was largely blocked in the presence of either heparin or the heparin/antifibrin IgG conjugate. Furthermore, reversal of this heparin-induced inhibition of the catalytic activity was readily achieved by the addition of an adequate amount of protamine.
MATERIALS AND METHODS

Reagents
Recombinant tPA (Alteplase), prepared by expression of cDNA encoding tPA in Chinese Hamster ovary cells, was purchased from Genentech Inc. (South San Francisco, CA). Human plasminogen (plasmin free), plasmin, fibrinogen, SPDP, and heparin-immobilized Sephadex beads were from Sigma (St. Louis, MO). The chromogenic substrate D-Val-leu-lys-p-nitroanilide (S-2251) was purchased from Pharmacia Hepar Inc. (Franklin, OH). Murine anti-fibrin IgG was from American Diagnostica Inc. (Greenwich, CT). The octapeptide containing 7 arginine residues and a cysteine residue at the Cterminal [ie, (Arg) 7 Cys] was synthesized and purified by the Biomedical Research Core Facilities at the University of Michigan (Ann Arbor, MI).
Preparation and Purification of the tPA/(Arg) 7 Cys
(Arg) 7 Cys and tPA were linked with the heterobifunctional cross-linking reagent SPDP using a 2-step procedure described previously (15) . In the first step, active 2-pyridyl disulphide groups were introduced in tPA by treating the protein at a concentration of 1 mg/mL in phosphate-buffered saline pH 8.2 with 5-fold molar excess of SPDP for 30 minutes at room temperature. In the second step, the SPDP-activated tPA and (Arg) 7 Cys were mixed in a 1:20 molar ratio in 0.1 M sodium acetate buffer (pH 4.5), and the mixture was incubated at room temperature for 3 hours. The remaining reactive thiol groups were alkylated by the addition of 1/100 (vol/vol) of 0.1 M sodium iodoacetate, and the reaction mixture was passed through a Sephadex G-25 (25 × 0.8 cm) column to remove unreacted reagents. Eluted tPA fraction was then applied to a heparin-Sephadex column (5 × 0.5 cm), and the column was washed with 0.4 M NaCl at 4 o C. After that, the heparin-bound tPA/(Arg) 7 Cys conjugate (ie, mtPA) was eluted with 2.0 M NaCl and desalted. A schematic description of the conjugation between (Arg) 7 Cys and tPA is included in Figure 2A . 
Preparation of Heparin/Anti-Fibrin IgG Conjugate
Heparin (1.0 g) was dissolved in 300 mL H 2 O at 0 o C. Sodium nitrite (NaNO 2 , 10 mg) was added to this solution, and the pH was adjusted to 2.7 by HCl. The reaction was stirred on ice for 20 minutes, and then the pH was adjusted to 7.0 with NaOH to stop the reaction. Reagents were removed by extensive dialysis against H 2 O, and samples were freeze-dried. The NaNO 2 -treated heparin was then dissolved in 0.3 M sodium acetate (pH 4.5) to achieve a concentration of 5.0 mg/mL. Anti-fibrin IgG was dissolved in 0.05 M sodium acetate (2.5 mg/mL), pH 4.5. A solution of 0.2 mL 100 mM NaIO 4 was then added. The reaction mixture was protected from light and mixed by tumbling for 1 hour at room temperature. To the mixture, 0.2 ml of 100 mM adipic acid dihydrazide was added and mixed by tumbling at room temperature for 2 hours. Excess NaIO 4 and adipic acid dihydrazide were removed by passing the reaction mixture through a Sephadex G-25 column (25 × 0.8 cm) equilibrated with 0.3 M sodium acetate buffer (pH 4.5).
A solution (0.5 mL) of the above-prepared NaIO 4 -oxidized anti-fibrin IgG was mixed with 0.1 mL of the NaNO 2 -treated heparin (5.0 mg/mL), and the mixture was tumbled overnight at 4 o C. Excess heparin was removed by passing the reaction mixture through a Sephadex G-100 (25 × 0.8 cm) column equilibrated with 0.15 M NaCl. The heparin/antifibrin IgG conjugates were purified by passing through a protamine-Sepharose (25 × 0.8 cm) column and eluted with 2.0 M NaCl. Heparin/anti-fibrin IgG conjugates were analyzed by SDS-7.5% polyacrylamide gels under nonreduced conditions, and anti-fibrin activity of heparin/anti-fibrin IgG conjugate was measured by enzyme-linked immunosorbent assay (ELISA). A schematic description of the conjugation between heparin and anti-fibrin IgG is included in Figure 2B .
Spectrophotometric Assay of Plasminogen Activation
Plasminogen activation was determined by monitoring the plasmin production using its specific chromogenic substrate S-2251. The initial rate of S-2251 hydrolysis in TBS (50 mM Tris-HCl containing 50 mM NaCl and 0.01% Tween 80, pH = 7.2) at 25 o C was determined by measurement of the absorbance at 405 nm at different time intervals in a microplate reader (BioRad, Hercules, CA) and expressed as A 405 /min 2 .
Fibrin Clot Lysis Assay
The activity of tPA was determined by fibrin clot lysis assay using fibrin-containing agarose plates.
The plates were prepared as follows: 5.0 mL lowmelting-temperature agarose solution (3.0%, in TBS) containing 2.5 U thrombin was mixed with 5.0 mL solution containing fibrinogen (5 mg/mL) at 37 o C. The reaction mixtures were poured into a 90-mm culture dish and incubated at 37 o C for 30 minutes until the fibrin clot became visible. To perform the assays, samples were added directly into the 3-mm sample wells made on the solidified fibrin-agarose gel and incubated at 30 o C overnight. Fibrin lysis was quantitatively estimated by comparing the size of the zone of the fibrin gel lysis of an unknown sample with that of the size of the zone of the fibrin gel lysis of standards prepared by known concentrations of tPA.
Binding of tPA (or mtPA) to Heparin-Sepharose Beads Solutions (0.1 mL) of tPA (or mtPA) in TBS were mixed with 0.02 mL heparin-Sephadex beads and incubated at room temperature for 5 minutes. The heparin-Sephadex beads were then rinsed with 0.1 mL plasma for 5 minutes, followed by additional washing with plasma (twice) and TBS (twice). The plasminogen-activation activity of tPA (or mtPA) bound to the heparin bead was assessed by measuring the initial rate of S-2251 hydrolysis (16) . The total amount of tPA (or mtPA) activity adsorbed to the heparin beads was determined by eluting the beads with 2.0 M NaCl. The percentage of inhibition of tPA (or mtPA) activity was estimated from the ratio of the tPA (or mtPA) activity adsorbed and de-sorbed from the heparin beads.
Assay of plasminogen, α α α α 2 -antiplasmin, and fibrinogen levels in plasma Plasminogen and α 2 -antiplasmin levels in plasma were determined according to the method described previously (17) . Fibrinogen level in plasma was estimated by determining activated partial thromboplastin time (APTT), which is inversely proportional to the fibrinogen concentration. In brief, thrombin of 500 U/mL (150 μL) was mixed with 150 μL diluted plasma, and APTT was measured using a FibroSystem (BBL). Figure 2A depicts the synthesis of the tPA/(Arg) 7 Cys conjugate. Approximately 40% of tPA activity was retained following the synthesis of this modified tPA (Table 1) . The majority of activity loss occurred during the purification step, in which the reaction mixture was purified using a heparin column. Elution with high salt resulted in the removal of unmodified tPA and mtPA with weak heparin-binding affinity; thus, a large decrease in tPA activity resulted. The heparinbinding ability of mtPA in TBS-diluted plasma (1:1) was increased to 76% compared with the 36% of the unmodified tPA (Table 1) .
RESULTS AND DISCUSSION
Synthesis of the tPA/(Arg) 7 Cys and Heparin/AntiFibrin IgG Conjugates
Heparin was conjugated to anti-fibrin IgG via an endpoint attachment ( Figure 2B ). After conjugation with heparin, anti-fibrin IgG showed an increase in its molecular weight detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) ( Table 2 ). This result was consistent with results of the heparin/anti-fibrin IgG conjugate composition assay detected using azure-A (for heparin) and Coomassie Blue (for protein) ( 
Characterization of the tPA/(Arg) 7 Cys
To determine if modified tPA still retained its catalytic functions, the plasmin activity produced by the mtPA-mediated plasminogen activation was measured using substrate S-2251.Compared with the specific activity of 5800 IU/μg protein of the parent tPA, the amidolytic activity of mtPA was estimated to be 3900 IU/μg protein. The activation of plasminogen by tPA and mtPA both followed the Michaelis-Menten kinetics, as evidenced by the presence of a linear double-reciprocal plot of the activation rate versus the plasminogen concentration ( Figure 3) . The Km value for mtPA (2.7 μM) was higher than that for tPA ( 1.1 μM) , respectively.
It is well recognized that fibrin selectivity is the major reason for the preferred use of tPA over other clinical thrombolytic agents. Research in the past has thoroughly demonstrated that the activity of tPA was greatly enhanced in the presence of fibrin(ogen). To further examine the effect of modification on tPA activity, responses of modified tPA to fibrinogen activation were measured and compared to that of the parent tPA. Figure 3B shows that there are differences in the kinetics of tPA-mediated plasminogen activation between tPA and mtPA. However, modificaton of tPA with the (Arg) 7 Cys peptide did not seem to significantly change its fibrin-binding ability, as plasminogen activation mediated by mtPA was still enhanced in the presence of fibrinogen.
Characterization of the Pro-Drug Feature of the Heparin/Protamine-Based mtPA Delivery System
To examine the prodrug feature of the heparin/protamine-based mtPA delivery system, the amidolytic activity of both tPA and mtPA bound on the heparin beads were compared. Sepharose beads containing immobilized heparin were added to the tPA or mtPA solution. To avoid any influences from heparin-unbound tPA or mtPA (free tPA or mtPA that might be released from heparin beads because of its weaker heparin-binding ability), the tPA-or mtPA-bound heparin beads were rinsed 3 times with plasma. As shown in Table 3 , less than 3% of tPA was capable of binding to heparin beads after the extreme washing, whereas 25% of the mtPA showed a strong heparin-binding ability. It was noteworthy that as much as 95% of the amidolytic activity of mtPA was blocked once it bound to the heparin beads (Table 3 ). This prodrug feature of the heparin-bound mtPA was further demonstrated by the fact that depletion of plasma plasminogen, α 2 -antiplasmin, and fibrinogen levels by heparin-bound mtPA were significantly reduced compared with the free mtPA. As shown in Table 4 , a significant increase in plasmin and a decrease in fibrinogen and plasminogen were observed when free mtPA was added into plasma and incubated at 18 o C for 12 hours. Conversely, there were almost no statistically significant changes in plasma plasminogen and plasmin levels when the same amount of heparin-bound mtPA was added. Because fibrinogen concentration was determined by APTT and because the presence of heparin would cause an increase in APTT, the slight decrease in fibrinogen concentration using the heparin-bound mtPA could be attributed to heparin-prolonged APTT but not necessarily to a real decrease in plasma fibrinogen concentration. The presence of a similar decrease in fibrinogen concentration in plasma treated with heparin beads only (data not shown) provided support for this assumption. To further demonstrate the utility of this heparin/protamine-based tPA delivery system, the in vitro fibrin clot lysis assay was performed. As shown in Figure 4 , mtPA bound to the heparin beads (Well #2) caused relatively insignificant clot lysis (<5%) compared to free mtPA (Well #1). When protamine was added to the heparin beadsbound mtPA (see Well #3), the area of clot lysis increased, indicating that heparin-induced blockage of the mtPA activity was reversed. These results were consistent with those in Table 3 , where chromogenic assay was used. On the basis of these findings, it is clear that heparin can be used to block the activity of mtPA (ie, to achieve the prodrug feature of our approach), and this inhibition can be reversed by the addition of protamine.
It should be pointed out that the success of the discussed heparin/protamine-based delivery system relies on two key binding conditions. One is that the binding of mtPA to heparin has to be stronger than that of anti-thrombin III so that mtPA can remain attached to heparin following administration. In this regard, previous studies conducted in our laboratory have demonstrated that the poly(Arg) 7 is the minimal heparin-binding sequence in protamine (18), and its binding to heparin is stronger than that of antithrombin III (19) . The other requirement is that the binding of mtPA to heparin should be weaker than that of protamine, so that heparin-induced inhibition on mtPA can be reversed by the addition of protamine. Indeed, our results obtained using the chromogenic assay (Table 3 ) and the fibrin clot lysis assay ( Figure 4 ) have shown that heparin-induced blockage of mtPA activity can be partially reversed by protamine. Because the binding strength of poly(Arg) 7 to heparin is comparable to that of protamine to heparin (20) , protamine concentration is vital to the release of mtPA from its heparin counterpart. Protamine at low concentration may not be sufficiently competitive to dissociate the binding between poly(Arg) 7 and heparin; in addition, our previous studies using the chromogenic assay showed that at high concentrations, protamine actually inhibited tPA-mediated conversion of plasminogen to plasmin (data not shown). Therefore, we hypothesize that the lack of a 100% reversal of mtPA activity in our experiments may simply be attributable to the use of an inadequate amount of protamine for heparin reversal. Therefore, more careful selection of the positively charged peptide (ie, with the required heparin-binding strengths) is necessary in the heparin/protamine delivery system for tPA delivery.
Because enhancing the targeting ability of the mtPA/heparin pro-drug had been proposed ( Figure  1 ), a heparin/anti-fibrin antibody conjugate instead of heparin was indicated for the actual application of our approach. Results in Figure 5 show that, like heparin by itself, the heparin/anti-fibrin IgG conjugate was also capable of blocking the activity of mtPA, but the inhibition on the mtPA activity (40-60%) by the heparin/anti-fibrin IgG conjugate was considerably lower than that by the heparin beads (>95%). It should be pointed out that in the experiments using the heparin beads, only mtPA that bound strongly to the heparin beads (25% of total mtPA) was involved in the inhibition studies. In contrast, in experiments using the anti-fibrin/heparin conjugates, different mtPA species with or without the sufficient heparin binding affinity were all involved in the inhibition study. Because the heparin-unbound mtPA was not separated from the reaction system, as it was in the experiments using heparin beads, the free mtPA (ie, not able to bind to the heparin/anti-fibrin IgG conjugate) present in the reaction mixture exerted plasminogen activation activity and, as a consequence, resulted in a reduced inhibition of mtPA activity by the heparin/anti-fibrin IgG conjugate.
In vitro experiments have demonstrated that tPA possesses a more specific fibrin-targeting ability than the other principal thrombolytics, urokinase and streptokinase (21, 22) . This characteristic provides the main impetus for the development of tPA as the thrombolytic agent of choice. Recombinant tPA as a thrombolytic agent is now widely used in acute myocardial infarction (23, 24) and venous thrombolic disease (25, 26) . However, recent clinical studies nevertheless show that clinical administration of tPA seems to exhibit less clot specificity than experimentally predicted, and the rate of hemorrhagic stroke associated with the use of tPA and streptokinase is statistically identical (11) . In this study, the feasibility and utility of the heparin/protamine-based approach for tPA delivery has been demonstrated in vitro. Further in vivo experiments to examine the overall utility of this approach are currently in progress in our laboratories.
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